FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317364532> ?p ?o ?g. }

• W2317364532 endingPage "692" @default.
• W2317364532 startingPage "692.16" @default.
• W2317364532 abstract "Background Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis, and The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has defined clinical core domains for assessment of PsA. Objectives In an investigator-initiated trial to evaluate the clinical efficacy of adalimumab in patients with PsA assessed by the Psoriatic Arthritis Response Criteria (PsARC), the American College of Rheumatology (ACR) response rates, and clinical core domains defined by GRAPPA. Methods Anti-TNF-naive PsA patients were included in a follow-up cohort study, with the following main inclusion criteria: PsA according to Moll and Wright criteria, ≥3 (of 76) swollen joints, ≥3 (of 78) tender joints, hand involvement (clinical swelling of ≥1 finger joint and/or ≥1 sausage finger), and clinical indication for anti-TNF therapy according to treating physician. Modified PsARC and ACR response rates were calculated. Last observation carried forward (LOCF) imputation was used for missing values at completed visits. Results Baseline characteristics of the 42 PsA patients were: 18 males/24 females, median (interquartile range) age 52 (41-64) years, joint disease duration 8.5 (5-15) years, and skin disease duration 23 (10-35) years. Disease activity parameters at baseline and week 24 were: high-sensitive CRP 4.62 (1.81-9.53) [week 24: 0.85 (0.66-2.88)*] mg/L, swollen joint count (SJC, 76) 8.5 (6-16) [w24: 0 (0-2)*], tender joint count (TJC, 78) 21.5 (11-41) [w24: 2(0-6)*], VAS pain 63 (49-74) [w24: 4 (17-34)] mm, VAS global 66 (49-78) [w24: 24 (6-44)*] mm, VAS physician 51 (41-65) [w24: 5 (2-12)] mm, HAQ-score 1.0 (0.4-1.5) [w24: 0.38 (0-0.88)], MASES 13-enthesis count 3 (0-6) [w24: 0 (0-6) NS], dactylitis count 0 (0-2) [w24: 0 (0-1) NS], sum NAPSI nail score 4 (0-31) [w24: 0 (0-6)*], physician’s global assessment for psoriasis (PGA)-score 2 (1-3) [w24: 1 (0-1)*], body surface area affected by psoriasis (BSA) 1 (0.9-2) [w24 0.9 (0-1)*] %, quality of life EQ-5D score 0.655 (0.559-0.708) [w24: 0.776 (0.660-1.00)*], *all P The table shows the Intention-To-Treat (ITT), and Completer Analysis (CA) for PsARC and ACR-response rates. Conclusions Adalimumab therapy had a high clinical efficacy as assessed by PsARC and ACR response rates, and caused improvement in all clinical core domains. More than 2/3 had a significant PsARC-response already after 2 weeks, whereas high treatment responses (ACR50/70) were primarily seen later. Disclosure of Interest None Declared" @default.
• W2317364532 created "2016-06-24" @default.
• W2317364532 creator A5001617758 @default.
• W2317364532 creator A5018187678 @default.
• W2317364532 creator A5043141865 @default.
• W2317364532 creator A5044135679 @default.
• W2317364532 creator A5060183493 @default.
• W2317364532 creator A5072664936 @default.
• W2317364532 creator A5073605126 @default.
• W2317364532 creator A5081905729 @default.
• W2317364532 date "2013-06-01" @default.
• W2317364532 modified "2023-10-14" @default.
• W2317364532 title "AB0946 Anti-TNF treated psoriatic arthritis: Course of composite disease activity measures and clinical core domains:" @default.
• W2317364532 doi "https://doi.org/10.1136/annrheumdis-2012-eular.946" @default.
• W2317364532 hasPublicationYear "2013" @default.
• W2317364532 type Work @default.
• W2317364532 sameAs 2317364532 @default.
• W2317364532 citedByCount "0" @default.
• W2317364532 crossrefType "journal-article" @default.
• W2317364532 hasAuthorship W2317364532A5001617758 @default.
• W2317364532 hasAuthorship W2317364532A5018187678 @default.
• W2317364532 hasAuthorship W2317364532A5043141865 @default.
• W2317364532 hasAuthorship W2317364532A5044135679 @default.
• W2317364532 hasAuthorship W2317364532A5060183493 @default.
• W2317364532 hasAuthorship W2317364532A5072664936 @default.
• W2317364532 hasAuthorship W2317364532A5073605126 @default.
• W2317364532 hasAuthorship W2317364532A5081905729 @default.
• W2317364532 hasConcept C119060515 @default.
• W2317364532 hasConcept C126322002 @default.
• W2317364532 hasConcept C141071460 @default.
• W2317364532 hasConcept C16005928 @default.
• W2317364532 hasConcept C198451711 @default.
• W2317364532 hasConcept C2776260265 @default.
• W2317364532 hasConcept C2777077863 @default.
• W2317364532 hasConcept C2777575956 @default.
• W2317364532 hasConcept C2780132546 @default.
• W2317364532 hasConcept C2780564577 @default.
• W2317364532 hasConcept C71924100 @default.
• W2317364532 hasConcept C72563966 @default.
• W2317364532 hasConcept C90924648 @default.
• W2317364532 hasConceptScore W2317364532C119060515 @default.
• W2317364532 hasConceptScore W2317364532C126322002 @default.
• W2317364532 hasConceptScore W2317364532C141071460 @default.
• W2317364532 hasConceptScore W2317364532C16005928 @default.
• W2317364532 hasConceptScore W2317364532C198451711 @default.
• W2317364532 hasConceptScore W2317364532C2776260265 @default.
• W2317364532 hasConceptScore W2317364532C2777077863 @default.
• W2317364532 hasConceptScore W2317364532C2777575956 @default.
• W2317364532 hasConceptScore W2317364532C2780132546 @default.
• W2317364532 hasConceptScore W2317364532C2780564577 @default.
• W2317364532 hasConceptScore W2317364532C71924100 @default.
• W2317364532 hasConceptScore W2317364532C72563966 @default.
• W2317364532 hasConceptScore W2317364532C90924648 @default.
• W2317364532 hasIssue "Suppl 3" @default.
• W2317364532 hasLocation W23173645321 @default.
• W2317364532 hasOpenAccess W2317364532 @default.
• W2317364532 hasPrimaryLocation W23173645321 @default.
• W2317364532 hasRelatedWork W1976666740 @default.
• W2317364532 hasRelatedWork W2026284061 @default.
• W2317364532 hasRelatedWork W2105833786 @default.
• W2317364532 hasRelatedWork W2401863604 @default.
• W2317364532 hasRelatedWork W2469713984 @default.
• W2317364532 hasRelatedWork W2762831095 @default.
• W2317364532 hasRelatedWork W3080369541 @default.
• W2317364532 hasRelatedWork W4210419598 @default.
• W2317364532 hasRelatedWork W4229733615 @default.
• W2317364532 hasRelatedWork W4324320300 @default.
• W2317364532 hasVolume "71" @default.
• W2317364532 isParatext "false" @default.
• W2317364532 isRetracted "false" @default.
• W2317364532 magId "2317364532" @default.
• W2317364532 workType "article" @default.